410 related articles for article (PubMed ID: 30007540)
1. Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling.
Rukhlenko OS; Khorsand F; Krstic A; Rozanc J; Alexopoulos LG; Rauch N; Erickson KE; Hlavacek WS; Posner RG; Gómez-Coca S; Rosta E; Fitzgibbon C; Matallanas D; Rauch J; Kolch W; Kholodenko BN
Cell Syst; 2018 Aug; 7(2):161-179.e14. PubMed ID: 30007540
[TBL] [Abstract][Full Text] [Related]
2. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
3. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
[TBL] [Abstract][Full Text] [Related]
4. Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.
Dhawan NS; Scopton AP; Dar AC
Nature; 2016 Sep; 537(7618):112-116. PubMed ID: 27556948
[TBL] [Abstract][Full Text] [Related]
5. Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy.
Degirmenci U; Wang M; Hu J
Cells; 2020 Jan; 9(1):. PubMed ID: 31941155
[TBL] [Abstract][Full Text] [Related]
6. Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node.
Scardaci R; Berlinska E; Scaparone P; Vietti Michelina S; Garbo E; Novello S; Santamaria D; Ambrogio C
Mol Oncol; 2024 Jun; 18(6):1355-1377. PubMed ID: 38362705
[TBL] [Abstract][Full Text] [Related]
7. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
Shao W; Mishina YM; Feng Y; Caponigro G; Cooke VG; Rivera S; Wang Y; Shen F; Korn JM; Mathews Griner LA; Nishiguchi G; Rico A; Tellew J; Haling JR; Aversa R; Polyakov V; Zang R; Hekmat-Nejad M; Amiri P; Singh M; Keen N; Dillon MP; Lees E; Ramurthy S; Sellers WR; Stuart DD
Cancer Res; 2018 Mar; 78(6):1537-1548. PubMed ID: 29343524
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of RAF dimers: it takes two to tango.
Cook FA; Cook SJ
Biochem Soc Trans; 2021 Feb; 49(1):237-251. PubMed ID: 33367512
[TBL] [Abstract][Full Text] [Related]
9. Classical RAS proteins are not essential for paradoxical ERK activation induced by RAF inhibitors.
Lai LP; Fer N; Burgan W; Wall VE; Xu B; Soppet D; Esposito D; Nissley DV; McCormick F
Proc Natl Acad Sci U S A; 2022 Feb; 119(5):. PubMed ID: 35091470
[TBL] [Abstract][Full Text] [Related]
10. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers.
Mazumdar T; Sen B; Wang Y; Peng S; Nicholas C; Glisson BS; Myers JN; Johnson FM
Anticancer Drugs; 2015 Sep; 26(8):835-42. PubMed ID: 26053277
[TBL] [Abstract][Full Text] [Related]
12. It takes two to tango--signalling by dimeric Raf kinases.
Baljuls A; Kholodenko BN; Kolch W
Mol Biosyst; 2013 Apr; 9(4):551-8. PubMed ID: 23212737
[TBL] [Abstract][Full Text] [Related]
13. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J
Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707
[TBL] [Abstract][Full Text] [Related]
14. SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers.
Jones GG; Del Río IB; Sari S; Sekerim A; Young LC; Hartig N; Areso Zubiaur I; El-Bahrawy MA; Hynds RE; Lei W; Molina-Arcas M; Downward J; Rodriguez-Viciana P
Nat Commun; 2019 Jun; 10(1):2532. PubMed ID: 31182717
[TBL] [Abstract][Full Text] [Related]
15. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
[TBL] [Abstract][Full Text] [Related]
16. The importance of Raf dimerization in cell signaling.
Freeman AK; Ritt DA; Morrison DK
Small GTPases; 2013; 4(3):180-5. PubMed ID: 23985533
[TBL] [Abstract][Full Text] [Related]
17. Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling.
Freeman AK; Ritt DA; Morrison DK
Mol Cell; 2013 Feb; 49(4):751-8. PubMed ID: 23352452
[TBL] [Abstract][Full Text] [Related]
18. SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics.
Boned Del Río I; Young LC; Sari S; Jones GG; Ringham-Terry B; Hartig N; Rejnowicz E; Lei W; Bhamra A; Surinova S; Rodriguez-Viciana P
Proc Natl Acad Sci U S A; 2019 Jul; 116(27):13330-13339. PubMed ID: 31213532
[TBL] [Abstract][Full Text] [Related]
19. Drug discovery: inhibitors that activate.
Cichowski K; Jänne PA
Nature; 2010 Mar; 464(7287):358-9. PubMed ID: 20237552
[No Abstract] [Full Text] [Related]
20. RAF kinase dimerization: implications for drug discovery and clinical outcomes.
Brummer T; McInnes C
Oncogene; 2020 May; 39(21):4155-4169. PubMed ID: 32269299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]